Kasumi-6 (ATCC® CRL-2775)

Organism: Homo sapiens, human  /  Cell Type: myeloblast  /  Tissue: peripheral blood  /  Disease: acute myeloid leukemia, subtype M2

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Tissue peripheral blood
Cell Type myeloblast
Product Format frozen
Morphology myeloid leukemia
Culture Properties suspension
Biosafety Level 1
Disease acute myeloid leukemia, subtype M2
Age 64 years adult
Gender male
Ethnicity Japanese
Applications
The Kasumi-6 cell line can serve as a model to study the cellular and molecular biology of the non-t(8;21) M2 type of myeloid leukemia and can elucidate the role of mutated C/EBPalpha in leukemogenesis.

Storage Conditions liquid nitrogen vapor phase
Karyotype 45, XY,-9,add(12)(p11),add(13)(p11) RefAsou H, et al. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene. Genes Chromosomes Cancer 36: 167-174, 2003. PubMed: 12508245
Derivation
The cell line was established from the blast cells of a myeloperoxidase-negative patient with relapsed acute myeloid leukemia (AML), FAB M2. The patient had received prior chemotherapy.
Clinical Data
64 years adult
Japanese
male
Antigen Expression
CD33+, CD13+, CD11b+, HLA-DR+, CD3-, CD14-, CD19-, CD41-, CD34
Genes Expressed

Myeloperoxidase, negative C/EBP-alpha, hemizygous mutation protein positive


Comments

Both the original leukemic cells and the Kasumi-6 cell line harbor a hemizygous point mutation in the gene encoding the CCAAT/enhancer binding protein alpha (C/EBPalpha), a critical myeloid transcriptional factor. 

The cells express C/EBPalpha protein but lack C/EBPalpha binding activity.

12-O-tetradecanoylphorbol-13-acetate (TPA) induces Kasumi- 6 cells to differentiate into adherent, monocytoid appearing cells. 

Differentiation Inducers: TPA

Complete Growth Medium RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate supplemented with 2 ng/ml human recombinant granulocyte macrophage colony stimulating factor (GM-CSF) and 20% fetal bovine serum
Subculturing Cultures can be established by centrifugation with subsequent resuspension at 2 x 105 viable cells/mL.
Maintain cell density between 2 x 105 and 1.5 x 106 viable cells/mL.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density).
Cryopreservation
Freeze medium: Complete growth medium supplemented with 10% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C
STR Profile
Amelogenin: X,Y
CSF1PO: 10,12
D13S317: 8,12
D16S539: 9,10
D5S818: 11
D7S820: 9,11
THO1: 6,9
TPOX: 8,9
vWA: 17
Population Doubling Time 55 hrs
Name of Depositor H Asou
Year of Origin January 1999
References

Asou H, et al. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene. Genes Chromosomes Cancer 36: 167-174, 2003. PubMed: 12508245

Asou H, et al. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene. Genes Chromosomes Cancer 36: 167-174, 2003. PubMed: 12508245

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Asou H, et al. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene. Genes Chromosomes Cancer 36: 167-174, 2003. PubMed: 12508245

Asou H, et al. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene. Genes Chromosomes Cancer 36: 167-174, 2003. PubMed: 12508245